Stockscreener 앱 받기
1.20
4.00%
-0.05
전일 마감가:
$1.25
열려 있는:
$1.27
하루 거래량:
21,928
Relative Volume:
0.26
시가총액:
$32.88M
수익:
-
순이익/손실:
$-37.38M
주가수익비율:
-0.962
EPS:
-1.2474
순현금흐름:
$-35.50M
1주 성능:
-7.69%
1개월 성능:
+3.45%
6개월 성능:
+11.11%
1년 성능:
-5.51%
1일 변동 폭
$1.20
$1.27
1주일 범위
$1.13
$1.3488
52주 변동 폭
$1.00
$1.55
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
ANTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.20 | 34.25M | 0 | -37.38M | -35.50M | -1.2474 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - Finviz
Sustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic Pain - Yahoo Finance
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - Business Wire
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - Yahoo Finance
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewswire
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Insider Monkey
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - Yahoo Finance
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewswire
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas - PR Newswire
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewswire
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - GlobeNewswire
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times
Kyverna Therapeutics to Report Topline Results from - GlobeNewswire
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - The Globe and Mail
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
Rhythm Pharmaceuticals to Announce Preliminary Data from - GlobeNewswire
Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 - PR Newswire
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC PatientsSlideshow (NASDAQ:TARA) 2025-12-04 - Seeking Alpha
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView — Track All Markets
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Relmada Therapeutics (RLMD) reports 9-month 92% CR for NDV-01 in NMIBC, eyes Phase 3 - Stock Titan
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Black Diamond Therapeutics (Nasdaq: BDTX) to present silevertinib Phase 2 trial results in Dec. 3 webcast - Stock Titan
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - GlobeNewswire
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Protara (Nasdaq: TARA) Sees 100% Success in TARA-002 Pediatric LM Phase 2 Study - Stock Titan
Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health - PR Newswire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
An 2 Therapeutics Inc 주식 (ANTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Day Lucy | Chief Financial Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
80,875 |
| Prior Stephen David | Chief Strategy Officer |
Jan 05 '26 |
Sale |
1.00 |
3,604 |
3,615 |
61,944 |
| Prior Stephen David | Chief Strategy Officer |
Jan 06 '26 |
Sale |
1.01 |
2,858 |
2,892 |
59,086 |
| Chanda Sanjay | Chief Development Officer |
Jan 06 '26 |
Sale |
1.01 |
5,956 |
6,027 |
75,823 |
| Chanda Sanjay | Chief Development Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
81,779 |
| Eizen Joshua M | See Remarks |
Jan 05 '26 |
Sale |
1.00 |
17,923 |
17,948 |
159,430 |
| Eizen Joshua M | See Remarks |
Jan 06 '26 |
Sale |
1.01 |
6,931 |
7,014 |
152,499 |
| Eizen Joshua M | See Remarks |
Nov 04 '25 |
Sale |
1.14 |
2,819 |
3,214 |
177,353 |
| Prior Stephen David | Chief Strategy Officer |
Nov 04 '25 |
Sale |
1.14 |
765 |
872 |
65,548 |
| Leonard Braden Michael | 10% Owner |
May 28 '25 |
Sale |
1.09 |
200,000 |
218,000 |
3,017,432 |
4.73%
0.92%
자본화:
|
볼륨(24시간):